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Abstract 
Computed tomography (CT) of the chest is one of the main diagnositic tools for coronavirus disease 2019 
(COVID-19) infection. To document the chest CT findings in patients with confirmed COVID-19 and their 
association with the clinical severity, we searched related literatures through PubMed, MEDLINE, Embase, 
Web of Science (inception to May 4, 2020) and reviewed reference lists of previous systematic reviews. A total 
of 31 case reports (3768 patients) on CT findings of COVID-19 were included. The most common comorbid 
conditions were hypertension (18.4%) and diabetes mellitus (8.3%). The most common symptom was fever 
(78.7%), followed by cough (60.2%). It took an average of 5.6 days from symptom onset to admission. The most 
common chest CT finding was vascular enlargement (84.8%), followed by ground-glass opacity (GGO) (60.1%), 
air-bronchogram (47.8%), and consolidation (41.4%). Most lung lesions were located in the lung periphery 
(72.2%) and involved bilateral lung (76%). Most patients showed normal range of laboratory findings such as 
white blood cell count (96.4%) and lymphocyte (87.2%). Compared to previous published meta-analyses, our 
study is the first to summarize the different radiologic characteristics of chest CT in a total of 3768 COVID-19 
patients by compiling case series studies. A comprehensive diagnostic approach should be adopted for patients 
with known COVID-19, suspected cases, and for exposed individuals. 
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Introduction 
A cluster of patients presenting with pneumonia 
of unknown etiology was one of the first signs to 
trigger suspicion of a common epidemical etiology of 
cases, weeks before the identification of coronavirus 
disease 2019 (COVID-19), a novel coronavirus, as the 
culprit pathogen by the Chinese as well as the WHO 
authorities [1-3]. Furthermore, healthcare workers 
have recognized that the virus was highly contagious 
to spread rapidly from person to person, in both 
symptomatic as well as asymptomatic individuals 
[4-6]. Currently, the number of confirmed cases has 
been greatly dynamic, increasing daily across the 
globe with multiple confirmed deaths. Moreover, 
recently, new variants including delta are globally 
spreading, and the crisis is rising again despite 









COVID-19 is caused by single-stranded RNA 
virus belonging to the family Coronaviridae in the 
order of Nidoviarles and is enveloped with a positive 
sense [8]. Its respiratory manifestations are caused by 
the beta genre of this zoonotic virus, similar to the 
severe acute respiratory syndrome coronavirus 
(SARS-CoV) and Middle East respiratory syndrome 
coronavirus (MERS-CoV) [8]. Transmission is 
achieved through large droplets generated by 
coughing or sneezing, as well as transport of the virus 
from surfaces into the mucosa of the mouth, nose, or 
eyes. Vertical transmission has also been reported [9]. 
Clinically, signs and symptoms of the disease are 
variable and fall on a spectrum ranging from 
asymptomatic to multi-organ failure or unfortunate 
death [9]. Respiratory manifestations are similar to 
other respiratory infections. They include but are not 
limited to cough, sore throat, and shortness of breath. 
In a subset of infected individuals, pneumonia and 
respiratory failure develop as part of severe 
complications, such as acute respiratory distress 
syndrome (ARDS) and acute lung injury, leading to 
most of the morbidities and mortalities [9]. This latter 
severe manifestation of infection is thought to be due 
to the robust increase in inflammatory cytokines, 
including interleukins [2, 7] and TNF- α, among 
others [2, 9]. One of the main diagnostic tools for lung 
involvement in the pathophysiology of the infection 
include computed tomography (CT) of the chest. In 
fact, given the high clinical sensitivity and specificity 
of chest CT, this imaging modality has been used in 
suspected infections with negative molecular testing 
[9, 10].  
Until now, there have been several systematic 
reviews and meta-analyses on chest CT findings 
associated with COVID-19 [11-15], but there are no 
comprehensive studies collecting all case series 
studies regarding the findings on chest CT in patients 
with confirmed COVID-19 and their association with 
clinical severity of viral infection. In this article, we 
show new perspectives on the most sensitive and 
specific CT imaging manifestations, the severity of the 
disease and the patient’s comorbidities. Previous 
studies have shown variable radiologic signs and 
findings of unknown clinical significance and 
prognosis. Findings from this review can serve as a 
guide and add to the growing knowledge of clinical 
perspectives of this pandemic.  
Methods 
Literature search strategy and selection 
criteria 
The Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines 
were followed for this systematic review and 
meta-analysis. We searched PubMed, MEDLINE, 
Embase, Web of Science, and limited the search to 
human findings and included reports published in 
any language. The search terms used were as follows: 
“coronavirus 19”, “COVID-19”, “and 2019-nCoV”, 
“novel coronavirus 2019”, “CT”, and “computed 
tomography”.  
We reviewed papers describing the findings on 
chest CT findings of COVID-19 positive patients 
during the extraction process. Because of the scarcity 
of evidence, papers without patient numbers were 
included. After the search process, we selected case 
series on the association of chest CT findings with the 
severity of the disease and patient mortality rates. In 
this process, we excluded in vitro or in vivo studies, 
genetic studies, and conference abstracts. The search 
was restricted to studies in humans. 
Four investigators did the search and manually 
screened the data. HK, JS, and SL separately extracted 
data, and KHL double-checked to determine whether 
the eligible articles met the inclusion criteria. The final 
search was carried out on May 24, 2020, and excluded 
544 overlapping or duplicated data sets. We first 
excluded duplicate articles and then labeled all the 
articles by examining titles, abstracts, and full texts in 
order. From 806 articles, a total of 31 case series with 
3768 patients were included for the primary outcome. 
A flow-chart of literature search is presented in Figure 
1. 
Analysis of included studies 
In this current review, descriptions of the lungs 
of COVID-19 infected patients based on CT scans 
reported in the studies were accessed. Studies only 
describing saturation and chest X-ray findings were 
not included when the diagnosis was not mentioned, 
and no CT scan was performed. Each case series is 
described in Table S4-S5. We organized the data of the 
patients’ characteristics, including age, sex, 
comorbidities, the period between symptom onset 
and admission/CT scan, clinical presentations, 
laboratory findings and types of treatments for 
analyses.  
Results 
Summary of previously published 
meta-analyses 
 A total of eleven meta-analyses on COVID-19 
related to Chest CT findings have been published. 
Detailed description of each study is shown in Table 
1. Three papers- Kim et al. [12], Xu et al [15] and 
Adams et al. [17] - summarized the sensitivity and 
specificity of chest CT as a diagnostic tool in 




COVID-19 pneumonia. However, there are no results 
about clinical presentations, laboratory findings, and 
treatment modalities. Four studies - Bao et al. [13], 
Zhu et al. [14], Sun et al. [20] and Lv et al. [21] - have 
conducted meta-analyses with only CT findings of 
COVID-19 patients, not describing clinical severity 
Only Wan et al. [18] summarized the both clinical 
characteristics and Chest CT findings of patients with 
COVID-19, but there is no results about laboratory 
findings and type of treatment. Other two papers - 
Park et al. [11] and Zheng et al. [16] - performed 
comparative analyses of CT findings comparing 
patients diagnosed in Wuhan with outside of Wuhan 
in China and the common patients with severe 
patients, respectively. Both studies contained no 
result about laboratory findings and treatment 
modalities. Chang et al. [18] summarized CT findings, 
clinical characteristics and outcomes only in small 
number of children without detailed laboratory 
findings or treatment in the manuscript.  
 
Table 1. Main characteristics and findings of the previous meta-analyses of chest CT in COVID-19 





Park et al. 
2020 [11] 
9 627 The role of chest CT in COVID-19 diagnosis is inconclusive. A comparative analysis of clinical presentations and 
CT findings was performed between patients 
diagnosed in Wuhan and outside of Wuhan in China - 
no significant findings about CT findings and no data 
about laboratory findings and type of treatment 
Kim et al. 
2020 [12] 
68 6218 The pooled sensitivity was 94% (95% CI: 91-96; I2=95%) and 
specificity was 37% (26-50; 83%) for chest CT. 
Summarized the sensitivity and specificity of chest CT 
as a diagnostic tool in COVID-19 pneumonia - there is 
no results about clinical presentations, laboratory 
findings, and treatment modalities 
Bao et al. 
(2020) [13] 
13 2738 Typical CT signs were GGO (83.3%), GGO with mixed consolidation 
(58.4%). The incidences were highest in the right lower lobe (87.2%), 
left lower lobe (81.4%), and bilateral lower lobes (65.2%). 
CT findings of patients with COVID-19 are 
summarized in this article - there is no results about 
clinical presentations, laboratory findings and type of 
treatment 
Zhu et al. 
(2020) [14] 
7 4121 Most patients presented bilateral lung involvement (73.8%, 95% CI: 
65.9-81.1) and the most common changes in lesion density were 
GGO (68.1, 56.9‐78.2).  
CT findings of patients with COVID-19 are 
summarized in this article - not mentioning clinical 
presentations, laboratory findings, and type of 
treatment 
Xu et al. 
(2020) [15] 
16 3186 Chest CT has a high sensitivity 92% (95% CI: 86-96), for detecting 
COVID-19, especially in a region with severe epidemic, which is 
helpful to early recognize suspicious cases and might contribute to 
confine epidemic. 
Summarized the sensitivity of chest CT as a diagnostic 
tool in COVID-19 pneumonia - there is no results 
about clinical presentations, laboratory findings, and 
treatment modalities 
Zeng et al. 
(2020) [16] 
15 2,451 Based on the CT images, the common patients were less frequent to 
exhibit consolidation (OR: 0.31), pleural effusion (0.19), 
lymphadenopathy (0.17), crazy-paving pattern (0.22), interlobular 
septal thickening (0.27), reticulation (0.20), traction bronchiectasis 
(0.40) with over 2 lobes nvolved (0.07) and central distribution (0.18) 
while more frequent to bear unilateral pneumonia (4.65) involving 1 
lobe (13.84) or 2 lobes (6.95) when compared with severe patients. 
The paper compared the common patients with severe 
patients – not comparing or mentioning about clinical 
presentations laboratory findings, and treatment 
modalities. 
Adams et al.  
(2020) [17] 
6 1431 Chest CT appears to have a relatively high sensitivity (92.9% to 
97.0%) in symptomatic patients at high risk of COVID-19, but it 
cannot exclude COVID-19. Specificity is poor (25.0% to 71.9%).  
Summarized the sensitivity of chest CT as a diagnostic 
tool in COVID-19 pneumonia - there is no results 
clinical presentations, laboratory findings, and type of 
treatment 
Chang et al. 
(2020) [18] 
9 93 In Fever occurred in 59% of the patients, while cough in 46%. 
Gastrointestinal symptoms (12%) were uncommon. There are 26% 
children are asymptomatic. The most common radiographic finding 
was GGO (48%). 
The paper summarized CT findings, clinical 
characteristics and outcomes only in small number of 
children (not for adults) - detailed laboratory findings 
or treatment are not described in the manuscrupt 
Wan et al. 
(2020) [19] 
14 1115 Chest CTs showed pure GGO (69%, 95% CI 58-80) and 70% (95% CI 
46-95) of cases showed a location preference for the right lower lobe, 
65% (58-73) of patients presented with ≥3 lobes involvement. In 
terms of clinical features, muscle soreness (21%, 95% CI 15-26) and 
diarrhea (7%, 4-10) were minor symptoms compared to fever (80%, 
74-87) and cough (53%, 33-72). 
CT findings and clinical presentations of patients with 
COVID-19 are summarized in this article - there is no 
results about laboratory findings and treatment 
modalities 
Sun et al.  
2020 [20] 
55 NA Pulmonary lesions more often involved bilateral lungs (78%, 95% 
CI: 45-100) and were more likely to have a peripheral (65.35%, 
25.93-100). GGO (58.05%, 16.67-100), consolidation (44.18%, 
1.61-71.46) and GGO plus consolidation (52.99%, 19.05-76.79) were 
the most common findings. 
Investigation of CT findings of COVID-19 
pneumonia– there is no findings about clinical 
presentations and laboratory findings 
Lv et al.  
2020 [21] 
103 5673 The sensitivity in case series was 96% (95% CI: 0.93-0.99). The most 
common imaging manifestation was GGO which was found in 75% 
(0.68-0.82) of the patients. The pooled probability of bilateral 
involvement was 84% (0.81-0.88). The most commonly involved 
lobes were the right lower lobe (84%, 95% CI: 0.78-0.90) and left 
lower lobe (81%, 0.74-0.87). 
CT findings of patients with COVID-19 are 
summarized in this article - there is no results about 
clinical presentations, laboratory findings and 
treatment modalities 









Baseline characteristics of patients included in 
case series 
 We included a total of 3768 patients with 
COVID-19 by compiling a total of 31 case series. 
Baseline characteristics are presented in Table 2. The 
mean age was 47.7 years. The percent ratio of males to 
females was approximately 48.5:51.7 (1826:1947). The 
most common comorbid conditions were 
hypertension (18.4%) and diabetes mellitus (8.3%). 
Cardio (7.1%) and cerebrovascular diseases (5.9%) 
were also common. The most frequent symptom was 
fever (78.7%), followed by cough (60.2%). 
Non-specific symptoms such as anorexia and fatigue 
or weakness were also highly prevalent, with their 
prevalence being 40.2% and 26.5%, respectively. Of 
the 17 types of initial symptoms examined, six were 
respiratory symptoms: cough, sputum, sore throat, 
nasal congestion or runny nose, shortness of breath, 
and hemoptysis. It took an average of 5.6 days from 
the onset of symptoms to hospital admission. 
 
Table 2. Patient characteristics of included case series 
Variables Mean or N/ total (%) 
Age (years) 47.7 
Sex (male/ female) 1826/ 1947 (48.5/ 51.7%) a 
Underlying diseases 
Hypertension 165/ 895 (18.4%) 
Diabetes mellitus 65/ 782 (8.3%) 
Cardiovascular disease 52/ 737 (7.1%) 
Cerebrovascular disease 13/ 219 (5.9%) 
Chronic liver disease 12/ 297 (4.0%) 
Chronic kidney disease 8/ 281 (2.8%) 
COPD 37/ 720 (5.1%) 
Malignancy 24/ 417 (5.8%) 
Pregnancy 2/ 62 (3.2%) 
Others b  
Initial symptoms 
Fever 2066/ 2624 (78.7%) 
Cough 1438/ 2390 (60.2%) 
Loss of appetite 74/ 184 (40.2%) 
Fatigue or weakness 457/ 1727 (26.5%) 
Sputum 425/ 1649 (25.8%) 
Dyspnea 211/ 1043 (20.2%) 
Myalgia 329/ 1937 (17.0%) 
Sore throat 189/ 1330 (14.2%) 
Chest tightness 71/ 635 (11.2%) 
Chill 46/ 448 (10.3%) 
Headache 147/ 1457 (10.1%) 
Nasal congestion or runny nose 67/ 804 (8.3%) 
Chest pain 35/ 487 (7.2%) 
GI symptom 96/ 1523 (6.3%) 
Shortness of breath 46/ 869 (5.3%) 
Hemoptysis 13/ 651 (2.0%) 
Others c  
Period from Sx onset to Adm (days) d 5.6 
Data are presented as mean value or the number of reported cases (N) compared to 
total cases. a In some included studies, inaccurate results were reported, so the sum 
does not match. b This contains diseases such as cerebral infarction, pulmonary 
emphysema, HIV infection, endocrine disease, surgical history and respiratory 
disease. c This contains symptoms such as lymphocytopenia, rhinobyon and snivel. 
d Total number of included cases was 351. Adm: admission; COPD: chronic 
obstructive pulmonary disease; GI: gastrointestinal; Sx: symptom. 
 
Characteristics of CT findings in patients with 
COVID-19 
 Table 3 shows the characteristic CT findings in 
patients with COVID-19. The most common finding 
was vascular enlargement (84.8%), while the second 
most common feature was ground-glass opacity 
(GGO) (60.1%), followed by air-bronchogram (47.8%), 
and consolidation (41.4%). Other findings such as 
crazy paving, septal thickening, and pleural effusion 
accounted for a small percentage. Most lung lesions 
were located in the lung periphery (72.2%) and were 
present bilaterally (76%). Regarding lobe distribution, 
the right lower lobe (RLL) was the area where 
COVID-19 lesions most commonly occurred (72.2%), 
followed by the left lower lobe (LLL) (69.6%). Right 
upper and middle lobe (RUL, RML), and left upper 
lobe (LUL) were involved at a similar rate respectively 
(49.2, 49.5, 51.8 %). 
 
Table 3. Chest CT findings of patients with COVID-19 
CT findings N/ total (%) 
Imaging finding 
Vascular enlargement 412/ 486 (84.8%) 
GGO 1311/ 2182 (60.1%) 
Air bronchogram 406/ 850 (47.8%) 
Consolidation 811/ 1960 (41.4%) 
Crazy paving 240/ 841 (28.5%) 
Septal thickening 280/ 1317 (21.3%) 
Pleural effusion 43/ 635 (6.8%) 
Transverse distribution 
Central 51/ 264 (19.3%) 
Peripheral 574/ 795 (72.2%) 
Central and Peripheral 71/ 170 (41.8%) 
Lung region distribution 
Unilateral 40/ 225 (17.8%) 
Bilateral 1335/ 1757 (76.0%) 
Lobe distribution 
RUL 147/ 299 (49.2%) 
RML 148/ 299 (49.5%) 
RLL 216/ 299 (72.2%) 
LUL 155/ 299 (51.8%) 
LLL 208/ 299 (69.6%) 
Data are presented as the number of reported cases (N) compared to total cases. CT: 
computed tomography; COVID-19: coronavirus disease 2019; GGO: ground glass 
opacity; RUL: right upper lobe; RML: right middle lobe; RLL: right lower lobe; 
LUL: left upper lobe; LLL: left lower lobe. 
 
Laboratory data of patients with COVID-19 
 Average white blood cell (WBC) count was 5.20 
×109/L and lymphocyte was 1.30 ×109/L, indicating 
both were within normal range. More specifically, 
most patients showed a normal range of WBC counts 
(96.4%), while increased or decreased levels were 
shown in only 2.2% and 1.4% of patients, respectively. 
Similarly, lymphocytes were in normal range in most 
cases (87.2%). C-reactive protein was elevated in 
31.7% of patients with a mean value of 13.7 mg/dL. 
Liver enzymes including aspartate transaminase 
(mean value: 36.93 U/L) and alanine 




aminotransferase (30.81 U/L) were within normal 
range, and lactic acid dehydrogenase (238.10 U/L) 
also showed normal level (Table 4). 
 
Table 4. Laboratory findings of patients with COVID-19 
Laboratoy findings Mean or N/ total (%) 
WBC 5.20 ×109/L a 
 Normal 1166/ 1210 (96.4%) 
 Increased 27/ 1210 (2.2%) 
 Decreased 17/ 1210 (1.4%) 
Neutrophil 3.50 ×109/L b 
Lymphocyte 1.30 ×109/L c 
 Normal 1130/ 1297 (87.2%) 
 Increased 55/ 1297 (4.2%) 
 Decreased 112/ 1297 (8.6%) 
C-Reactive Protein 13.7 mg/dL d 
 Increased 376/ 1187 (31.7%) 
Aspartate aminotransferase 36.9 U/L e 
Alanine aminotransferase 30.8 U/L e 
Lactic acid dehydrogenase 238.1 U/L f 
Data are presented as mean value or the number of reported cases (N) compared to 
total cases. Total numbers of included cases are a 1171, b 1004, c 1329, d 1187, e 259, 
and f 1082. COVID-19: coronavirus disease 2019; WBC: white blood cell. 
 
Treatment of patients with COVID-19 
 About 17.7% of patients received antiviral 
treatment, and 9.9% of patients had oxygen treatment. 
In the intensive care unit, 41 (1.1%), 4 (0.1%), and 2 
(0.05%) patients received mechanical ventilator, 
extracorporeal membrane oxygenation (ECMO), and 
continuous renal replacement therapy (CRRT), 
respectively. Interestingly, plasminogen therapy was 
also tried in 13 patients with COVID-19 (Table 5). 
 
Table 5. Treatments of patients with COVID-19 
Treatments N (%) 
Anti-coronavirus treatment  668 (17.7%) 
Glucocorticoids 139 (3.7%) 
Oxygen therapy 373 (9.9%) 
Mechanical ventilator  41 (1.1%) 
Plasminogen therapy 13 (0.3%) 
ECMO  4 (0.1%) 
CRRT  2 (0.05%) 
Data are presented as the number of reported cases (N) compared to total cases 
(n=3768). COVID-19: coronavirus disease 2019; ECMO: extracorporeal membrane 
oxygenation; CRRT: continuous renal replacement therapy. 
 
Discussion 
 Up to the best of our knowledge, there have 
been 11 meta-analyses about Chest CT findings of 
COVID-19 have been identified until now (Table 1). 
However, 4 papers [13, 14, 20, 21] simply described 
CT findings of patients with COVID-19. Another 3 
meta-analyses [12, 15, 17] were only for sensitivity or 
specificity values of chest CT as a diagnostic tool of 
COVID-19. The other papers analyzed with partial 
sample sizes (comparative analyses between two 
groups [11, 16], children [18], ect.) Among these 
meta-analyses, there has been no comprehensive 
studies collecting all case series studies on data 
regarding the findings on chest CT in patients with 
confirmed COVID-19 and their association with the 
clinical severity, laboratory findings and treatment 
modalities of the viral infection. 
 Clinical deterioration by COVID-19 is 
characterized by ARDS due to acute lung injury, 
cytokine storm syndrome, and multiple organ failure. 
Among them, acute lung damage is the most 
representative clinical complication due to COVID-19 
and is the starting point for all other serious clinical 
complications [22, 23]. As already shown in previous 
epidemics, including severe acute respiratory 
syndrome (SARS) and middle east respiratory 
syndrome (MERS), the coronavirus enters the cell by 
using angiotensin-converting enzyme-2 receptor 
(ACE2R) [24]. The ACE2Rs are mainly distributed in 
alveolar epithelial cells of the lungs, and thereby 
mediate direct lung injury by the coronavirus [25, 26]. 
However, careful analysis of serious complications 
might offer a window of opportunity in the 
management of the condition. The radiographic 
information of a chest CT scan has the potential to 
provide valuable information and assist healthcare 
workers in predicting the acuity of the infection and 
in categorizing patients at low, medium, and high risk 
of mortality from the disease. 
Most medical guidelines consider a chest CT 
scan as a useful diagnostic measure to complement for 
a RT-PCR test in spite of low specificity and 
unwanted exposure of radiation [8, 27, 28]. Chest CT 
provides information to assess clinical severity and 
helps to predict clinical progress at the same time as 
diagnosis [29]. 
Pneumonia by various viruses, including novel 
coronavirus, shares radiologic characteristics that are 
different from bacterial pneumonia. Despite a few 
differences according to pathogenic mechanisms, 
viral pneumonia is commonly characterized by 
bilateral lung involvement and a GGO pattern that 
often show mixed appearance with consolidative 
lesions. In addition, viral pneumonia is mainly 
distributed in the lung periphery [30]. Especially, in 
the COVID-19 pandemic, the radiologic 
characteristics of pneumonia caused by SARS and 
MERS coronavirus are something to be noted. The 
two diseases have shown that the mixed lesions occur 
mainly in the peripheral and lower regions of both 
lungs [8].  
Several researchers have reported the radiologic 
characteristics of COVID-19 since the initial outbreak 
[31]. Such information could provide important clues 
in understanding the pathogenic mechanism of 
SARS-CoV-2 and might play an important role in 




early diagnosis along with serologic testing [8, 31], 
even though the argument over the role of chest CT in 
COVID-19 diagnosis still persists [12, 28]. In a study of 
51 patients diagnosed with COVID-19, pneumonia 
mainly involved both lungs (86% of total patients / 
97% of total lesions), and the lung lesions were 
distributed across multiple sites in more than 4 lobes 
(63% / 90%) [32]. In addition, it occurred frequently in 
lower lobes (90% / 53%) and were mainly distributed 
in the posterior (80% / 89%) and peripheral areas of 
the lung (86% / 91%). Radiologic features of 
pneumonia from COVID-19 may depend on severity. 
A recent study divided COVID-19 into 5 stages 
(ultra-early, early, rapid progress, consolidation, and 
dissipation stages) and described the radiologic 
features of each stage [27]. According to this study, 
single, double, or scattered GGO lesions were 
observed in the ultra-early stage, and during the early 
stage, the GGO patterns gradually expanded with the 
onset of interlobular interstitial edema. In the rapid 
progress stage, as inflammation intensified, the 
exudate in alveoli spread into nearby alveoli and 
interstitial spaces, and the GGO lesion progressed to 
consolidation with signs of air-bronchogram. In the 
consolidation stage, large scale patchy consolidation 
was clearly present. Lastly, in the dissipation stage, 
the existing consolidation was gradually absorbed 
and faded, the interlobular septum became relatively 
clear, and opacity of the reticular pattern was mainly 
observed. 
Compared to 11 previous published 
meta-analyses, our study showed different the 
radiologic characteristics of chest CT in a total of 3768 
COVID-19 patients by compiling case series studies. 
The most common feature of the CT findings of 
COVID-19 was vascular enlargement (or thickening) 
(Table 3). Although the finding is somewhat 
non-specific and the underlying mechanisms are 
unclear, a recent study indicated that it could be 
an important point that distinguishes COVID-19 
pneumonia from non-COVID-19 pneumonia, 
and a useful indicator to suspect COVID-19 
infection at an early stage [31, 33]. The second 
most common CT finding in COVID-19 
pneumonia was GGO, which has already been 
considered as a typical feature in viral 
pneumonia, including COVID-19. The GGO is a 
radiologic opacity that does not obscure the 
contours of close broncho-vascular structures, 
which suggests the existence of transudate or 
exudate in alveoli, but the fluid amount is not 
large enough to make a large contrast with the 
surrounding air spaces. Thus, the GGO pattern 
suggests early lesions such as alveolitis, and, as 
the disease progresses, it develops into a 
consolidative lesion by the accumulation of 
fibrinous exudate. In the GGO lesion, the alveoli 
are relatively better aerated compared to the 
severity of radiologic findings, such that 
asymptomatic COVID-19 infections are often 
found with significant abnormal findings in 
chest radiography. Another common CT finding 
for COVID-19 was air-bronchogram. This was 
reported at a similar rate as consolidation in our 
study because it has the same clinical 
significance as a secondary lesion following 
consolidation. Consolidation in the lung means 
that the functional space of alveoli has been lost 
by inflammatory exudates, thus predicting 
clinical exacerbation. Many studies, including 
this study, report mixed GGO and consolidation 
as a typical feature of COVID-19 [34], and these 
mixed findings are understood as a process of 
transition in which the GGO lesions worsen into 
 
 
Figure 1. Flow chart of literature search. 




a consolidative stage rather than independent lesions. 
Other chest CT findings of COVID-19 included crazy 
paving, which is thought to be one of the worsening 
lesions of the GGOs that does not progress to 
consolidation. Based on the localization of chest CT 
findings of COVID-19 in this study, as in other 
existing studies, peripheral distribution is mainly 
shown, and the lesions usually involve the right lung 
and lower lobes. Although there is no clear evidence, 
these findings may be associated with the inflow of 
coronavirus particles through breathing. When the 
coronavirus particles enter the lung, it is easier to 
contact alveolar epithelial cells in the lung periphery 
where airflow slows down. Also, in regard to the 
preference for specific lung lobes in occurrence of 
COVID-19 pneumonia, we could understand such a 
tendency by referring to the volume of each lung 
segment. In a study of COPD patients, the assessment 
of the lung lobar volumes in the control group 
through three-dimensional (3D) CT showed that RLL 
had the largest volume and that the volumes got 
smaller in the order of LUL, LLL, RUL, and RML [35]. 
Although these results do not exactly correspond to 
the localization of pneumonia from COVID-19 shown 
in this study, the preferred area for the occurrence of 
pneumonia seems to be associated with the 
physiologic lobar volumes. 
A comprehensive diagnostic approach should be 
adopted for patients with known COVID-19, 
suspected cases, and for exposed individuals. The 
radiologic imaging, clinical picture, laboratory testing, 
and molecular confirmatory assays should be 
analyzed in a complementary and accumulative 
manner. Healthcare providers should consider all 
clinical cues before planning management and 
treatment.  
Conclusions 
 In this study, we provide information on the 
characteristics of CT findings of COVID-19 from a 
large number of patients through a comprehensive 
analysis of existing case series. The understanding of 
radiologic characteristics in COVID-19 can help assess 
and predict the clinical course of the disease, and 
provide a useful measure for early diagnosis of 
COVID-19. Above all, understanding the underlying 
mechanisms of radiologic patterns in COVID-19 is 
likely to provide a clue on the clinical properties of 
SARS-CoV-2 that causes serious lung damage with 
high infectivity. The findings and hallmarks in the 
chest CT could assist in predicting the severity and 
acuity, progression, prognosis, and risk of mortality of 
infection. 
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